Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859267 | 0.83 | KDM4E (0.46) | CYP2C9SMN1; SMN2EPHX1MEN1KMT2A | |
| SCHEMBL669242 | 0.80 | POLB (0.35) | CYP2C9SMN1; SMN2POLBALPLALPI | |
| SCHEMBL6289243 | 0.79 | EPHX1 (0.37) | CYP2C9SMN1; SMN2EPHX1MEN1KMT2A | |
| SCHEMBL669976 | 0.78 | CYP2C9 (0.35) | CYP2C9SMN1; SMN2POLBALPLALPI | |
| SCHEMBL668795 | 0.78 | ALPL (0.34) | CYP2C9SMN1; SMN2RAB9APOLBALPL | |
| SCHEMBL18972850 | 0.78 | EPHX1 (0.38) | CYP2C9SMN1; SMN2EPHX1MEN1KMT2A | |
| SCHEMBL669240 | 0.77 | ALPL (0.33) | CYP2C9SMN1; SMN2ALPLALPIALPG | |
| SCHEMBL29420093 | 0.77 | KDM4C (0.45) | KDM5BKDM4EALDH1A1TSHR | |
| SCHEMBL11281186 | 0.75 | EPHX1 (0.44) | CYP2C9SMN1; SMN2EPHX1MEN1KMT2A | |
| SCHEMBL22366261 | 0.75 | LMNA (0.39) | CYP2C9SMN1; SMN2EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162039-B | Synthesis method of visible light mediated butanediamide compound | 河南师范大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-119350116-A | Method for synthesizing itaconic acid compound | 南京工业大学 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| CN-115385858-B | Photocatalytic preparation method of 2-phenyl-2H-indazole-3-carboxamide compound | 河南师范大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-115403519-B | Synthesis method of N-substituted isonicotinamide compound driven by visible light | 河南师范大学 | 2024-03-01 | — | — | CN | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116162039-A | Synthesis method of visible light mediated butanediamide compound | 河南师范大学 | 2023-05-26 | — | — | CN | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| EP-0067463-B1 | A PROCESS FOR THE PREPARATION OF ISOCYANATES AND/OR DERIVATIVES THEREOF | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-03-12 | — | — | EP | disclosed |
| US-4430262-A | Preparation of isocyanates and/or derivatives thereof | SHELL OIL COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| EP-0067463-A1 | A process for the preparation of isocyanates and/or derivatives thereof | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM5B 2357/4885CYP2C9 34/4885SMN1; SMN2 4640/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | KDM5B 646/4885CYP2C9 226/4885SMN1; SMN2 3375/4885 |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | KDM5B 2551/4885CYP2C9 429/4885SMN1; SMN2 2545/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | KDM5B 2126/4885CYP2C9 277/4885SMN1; SMN2 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.